Orforglipron
Also known as LY3502970
Orforglipron is an investigational oral, non-peptide GLP-1 receptor agonist studied for obesity and type 2 diabetes. Because it is a small molecule rather than a peptide, it does not require injection or the cold-chain handling many GLP-1 peptides need. Late-stage trials have reported average weight reductions comparable to some injectable GLP-1 agents, though it has not yet received regulatory approval. Ongoing studies continue to evaluate its long-term efficacy and safety.
Reported benefits
- Oral administration avoids the need for injections
- Associated with meaningful average weight loss in late-stage trials
- May improve glycemic control
- No cold-chain storage requirement reported for the tablet formulation
How it works
Orforglipron binds to and activates the GLP-1 receptor despite being structurally unrelated to the native GLP-1 peptide. Receptor activation slows gastric emptying and reduces appetite signaling in the central nervous system, similarly to peptide GLP-1 agonists, but the oral small-molecule format avoids the manufacturing and administration complexity of injectable peptides.
Dosing ranges
| Tier | Dose | Frequency |
|---|---|---|
| Low | 3 mg | once daily |
| Moderate | 12 mg | once daily |
| High | 36 mg | once daily |
Estimate your dose
Dose estimator
Educational estimate for Orforglipron, scaled to body size. Not medical advice.
Read before using
This tool produces a rough, educational estimate by scaling commonly-published research ranges to lean body mass. It is not a prescription, medical advice, or a substitute for a licensed clinician. Most peptides use fixed dosing, not weight-based dosing. Individual needs vary. You are solely responsible for how you use this information.
Mixing & syringe units
Target dose follows the estimate above. Change it there, or edit it directly below.
Reconstitution calculator
How much water to add and how many insulin-syringe units to draw for Orforglipron. Educational only.
Draw to this mark
240units
= 2.4 mL for a 12 mg dose
Concentration
5 mg/mL
Doses per vial
0
This dose needs 240 units, more than a 100-unit syringe holds. Add more water, split the dose, or use a larger syringe.
A U-100 syringe reads 100 units per mL. This is a reconstitution math helper only, not a prescription or dosing advice. Verify every calculation and consult a qualified healthcare provider.
Possible side effects
Stacking notes
Not established; combination with other GLP-1 agents is not supported by published research.
Common protocols
Common questions
What is Orforglipron used for?
Orforglipron is an investigational oral, non-peptide GLP-1 receptor agonist studied for obesity and type 2 diabetes. Because it is a small molecule rather than a peptide, it does not require injection or the cold-chain handling many GLP-1 peptides need. Late-stage trials have reported average weight reductions comparable to some injectable GLP-1 agents, though it has not yet received regulatory approval. Ongoing studies continue to evaluate its long-term efficacy and safety. Reported benefits include oral administration avoids the need for injections, associated with meaningful average weight loss in late-stage trials, may improve glycemic control.
What is a typical Orforglipron dose?
Reported ranges run 3-36 mg. A low protocol is 3 mg once daily, and a high protocol is 36 mg once daily. This is reference information, not a dosing recommendation.
What is the half life of Orforglipron?
Approximately 1-2 days, supporting once-daily oral dosing. That is what sets the dosing frequency, and it is why the timing guidance is morning, empty stomach.
How is Orforglipron administered?
Oral: by mouth. Non-peptide small-molecule GLP-1 agonist taken as an oral tablet, distinguishing it from injectable peptide GLP-1 agonists.
How long is a Orforglipron cycle?
Continuous daily use with titration in trial protocols on, followed by Not established outside of trial settings off.
What are the side effects of Orforglipron?
Reported side effects include nausea, vomiting, and diarrhea, especially during dose escalation, decreased appetite, potential gallbladder-related events, long-term safety data remain limited outside of trial settings. Evidence level for this compound is moderate evidence.
Partner offer · $20 off
When did you last
check your blood work?
Regular blood work catches changes early. At-home collection with free pickup, 50+ biomarkers, and results in 72 hours.
- 1Order your kitTakes two minutes online, $20 off with this link.
- 2Collect at homePainless draw with free home pickup, no lab visit.
- 3Results in 72 hours50+ biomarkers with clear optimal ranges.
Partner offer · opens rythm.health
Educational use only, not medical advice. This profile is provided for research and educational purposes. Orforglipron may be a research compound or a prescription medication; nothing here is intended to diagnose, treat, cure, or prevent any disease. Dosing figures reflect commonly-published research ranges, not a prescription. Consult a qualified healthcare provider before making any health decision. Read the full disclaimer →